Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Influx HealthtechNSE:INFLUX -2.71%21 Days Payable is 71.33 as of Mar. 2026, which is 15% below its 10-year median of 83.81. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 925 Drug Manufacturers companies, Influx Healthtech ranks better than 53.19% on this metric.
The historical rank and industry rank for Influx Healthtech's Days Payable or its related term are showing as below:
NSE:INFLUX'
s Days Payable Range Over the Past 10 Years
Min: 69.56 Med: 83.81 Max: 110.28
Current: 95.22
During the past 5 years, Influx Healthtech's highest Days Payable was 110.28. The lowest was 69.56. And the median was 83.81.
NSE:INFLUX's Days Payable is ranked better than 53.19% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs NSE:INFLUX: 95.22
Influx Healthtech's Days Payable
declined
from Mar. 2025 (127.53) to Mar. 2026 (71.33).
It may suggest that Influx Healthtechaccelerated paying its suppliers.
Influx Healthtech Days Payable Related Terms
Influx Healthtech Days Payable Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's Days Payable distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Influx Healthtech's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Influx Healthtech (NSE:INFLUX) has a Days Payable of 71.33 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Influx Healthtech and its competitors. This is 15% below median its historical median of 83.81. Over the past decade, Influx Healthtech's Days Payable has ranged from 69.56 to 110.28. According to the industry distribution chart, Influx Healthtech ranks #433 out of 925 companies in the Drug Manufacturers industry, placing it in the top 46.8%.
Is Influx Healthtech's Days Payable too high?
Influx Healthtech's current Days Payable of 71.33 is 15% below median its 10-year median of 83.81. Over the past 10 years, this metric has ranged from a low of 69.56 to a high of 110.28. The Drug Manufacturers industry median Days Payable is 90.38. Influx Healthtech's value of 71.33 is 21.1% below this industry median. Based on the distribution chart, Influx Healthtech ranks #433 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #433 out of 925 companies for Days Payable. This puts Influx Healthtech in the upper half of its industry. The industry median Days Payable is 90.38. Influx Healthtech's value of 71.33 is 21.1% below this benchmark. Historically, Influx Healthtech's own Days Payable has ranged from 69.56 to 110.28 over the past decade. While the company's 10-year median is 83.81 vs. the industry median of 90.38, Influx Healthtech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current Days Payable of 71.33 is 21.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current Days Payable is 71.33, which is 15% below median its own 10-year median of 83.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current Days Payable of 71.33. The current Days Payable is 71.33, which is 15% below median its 10-year median of 83.81 and 21.1% below the Drug Manufacturers industry median of 90.38. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current Days Payable is 71.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score
Get the complete analysis for NSE:INFLUX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 
